1. Home
  2. NAAS vs BMEA Comparison

NAAS vs BMEA Comparison

Compare NAAS & BMEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo NaaS Technology Inc.

NAAS

NaaS Technology Inc.

HOLD

Current Price

$2.59

Market Cap

50.8M

ML Signal

HOLD

Logo Biomea Fusion Inc.

BMEA

Biomea Fusion Inc.

HOLD

Current Price

$0.60

Market Cap

42.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NAAS
BMEA
Founded
2019
2017
Country
China
United States
Employees
N/A
37
Industry
Other Specialty Stores
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
50.8M
42.4M
IPO Year
2017
2021

Fundamental Metrics

Financial Performance
Metric
NAAS
BMEA
Price
$2.59
$0.60
Analyst Decision
Buy
Analyst Count
0
8
Target Price
N/A
★ $6.57
AVG Volume (30 Days)
15.3K
★ 2.2M
Earning Date
11-29-2026
11-03-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 69.19
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.80
$0.58
52 Week High
$4.10
$2.24

Technical Indicators

Market Signals
Indicator
NAAS
BMEA
Relative Strength Index (RSI) 26.42 22.67
Support Level $2.23 N/A
Resistance Level $2.70 $1.47
Average True Range (ATR) 0.16 0.11
MACD -0.05 -0.06
Stochastic Oscillator 10.99 2.92

Price Performance

Historical Comparison
NAAS
BMEA

About NAAS NaaS Technology Inc.

Naas Technology Inc is an electric vehicle charging service provider in China, whose vision is to power the world with carbon-neutral energy. It offers an integrated set of online solutions to charging station operators, a wide range of offline services that simplify the daily operations of charging station operators, and non-charging services such as food and beverage services to station operators.

About BMEA Biomea Fusion Inc.

Biomea Fusion Inc is a a clinical stage diabetes and obesity medicines company focused on the discovery and development of oral, small molecule drugs to treat and improve the lives of patients with diabetes, obesity, and other metabolic diseases. It operate as an organization centered on two of its core drug candidate development programs: (i) icovamenib, its clinical program's drug candidate, currently being developed as an orally bioavailable, and selective, covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity, and (ii) BMF-650, its investigational, next-generation oral glucagon-like peptide-1 GLP-1 receptor agonist in development for the treatment of obesity.

Share on Social Networks: